BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
13 nov. 2024 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
06 nov. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
28 oct. 2024 09h00 HE
|
BioCardia, Inc.
BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial.
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
18 sept. 2024 08h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09 sept. 2024 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 août 2024 08h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
29 août 2024 08h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
21 août 2024 07h00 HE
|
BioCardia, Inc.
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
13 août 2024 16h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
07 août 2024 07h00 HE
|
BioCardia, Inc.
BioCardia will provide a Q2 2024 corporate update and report its financial results by conference call on Tuesday August 13, 2024